Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belvedere: PDS in nAMD
NCT04853251Phase 4Active, not recruiting
- Sponsor
- Genentech
- Start
- Dec 2021
- Primary completion
- Jul 2027
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Genentech. Started Dec 2021; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04853251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853251.